Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Xiaofeng Li, Yueming He, Jinfeng Zhu, Hongxia Pang, Yongwei Lin, Jinyang Zheng

Oncotarget · 2018 · 15 citations · 26 references

DOIFull text

Open access

Concepts

Abstract

// Xiaofeng Li 1 , Yueming He 2 , Jinfeng Zhu 1 , Hongxia Pang 1 , Yongwei Lin 1 and Jinyang Zheng 3 1 Department of Oncology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China 2 Department of Respiratory Diseases, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China 3 Department of Pathology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China Correspondence to: Jinyang Zheng, email: Listar@tom.com Keywords: angiogenesis; apatinib; sarcomatoid carcinoma; targeted therapy Received: September 29, 2017      Accepted: March 17, 2018      Published: September 14, 2018 ABSTRACT Sarcomatoid carcinoma is a rare malignancy characterized by a combination of epithelial and sarcoma or sarcoma-like components. In this study, we reported one case of pulmonary sarcomatoid carcinoma and evaluated the safety and efficacy of apatinib, a tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptor 2, in treating this disease. The tumor mass was detected in the left lung of a 75-year-old man and showed positive immunostaining for cytokeratin (CK) 7, CK8, smooth muscle actin, CD31, and CD34. Next-generation sequencing analysis identified 4 mutations in NF1 (p.Q347Sfs * 29), CDKN2A (p.G23V), ERBB3 (p.V104L), and TP53 (p.V157F) genes. The patient was given apatinib (250 mg) orally once per day. Sustained tumor regression was observed after apatinib treatment. There was no sever complication associated with apatinib therapy. In conclusion, apatinib-based targeted therapy may represent an important option for patients with sarcomatoid carcinoma.

References

26